Bio-Techne Corporation (TECH)
Valuation Overview•Is Bio-Techne Corporation Overvalued or Undervalued?
Trading at a discount compared to peers, but the underlying intrinsic cash flows struggle to support the current price.
Moderate quality score of 65/100, reflecting stable operating margins and manageable leverage.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street sentiment is generally neutral alongside robust expected earnings growth. This is paired with healthy capital returns, driven predominantly by aggressive share repurchases.
TECH demonstrates adequate business quality with stable profitability. This is supported by a highly conservative balance sheet featuring strong liquidity and pristine Altman Z safety.
The company exhibits steady, low-single-digit revenue growth however, earnings have severely contracted over the same period. Operating efficiency remains adequate with margins around 12.7%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $311.4M | +5.2% | +3.3% | +10.5% | +10.4% | |
| EBITDA | $99.7M | — | -18.9% | — | — | |
| Net Income | $51.1M | -56.3% | -35.4% | — | -3.8% | |
| EPS (Diluted) | $0.32 | -56.2% | -34.8% | -20.5% | -4.4% | |
| Free Cash Flow | $77.6M | +8.7% | -2.9% | +10.8% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 65.0% | 66.3% | 67.1% | 66.8% |
| Operating Margin | 12.7% | 17.5% | 21.0% | 21.7% |
| Net Margin | 9.0% | 15.2% | 17.1% | 18.4% |
| FCF Margin | 22.3% | 20.1% | 23.8% | 23.3% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.55 | $0.53 | -3.6% | ||
| Q1'26 | $0.43 | $0.46 | +7.0% | ||
| Q4'25 | $0.42 | $0.42 | -0.3% | ||
| Q3'25 | $0.50 | $0.53 | +6.1% | ||
| Q2'25 | $0.51 | $0.56 | +10.2% | ||
| Q1'25 | $0.39 | $0.42 | +8.8% | ||
| Q4'24 | $0.38 | $0.42 | +10.5% | ||
| Q3'24 | $0.49 | $0.49 | -1.0% |
Total return is +16.2% (1Y), lagging the benchmark by -8.8%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -2.6% | -11.9% | — |
| 1Y | +16.2% | -8.8% | +0.6% |
| 3YCAGR | -8.7% | -29.8% | +1.2% |
| 5YCAGR | -11.2% | -25.1% | +1.5% |
| 10YCAGR | +8.2% | -5.9% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Bio-Techne Corporation (TECH) valuation, health, and returns.
Bio-Techne Corporation is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Slightly cheap versus peers compared to industry peers. overvalued (implying -49.8% downside from DCF intrinsic value of $29.07)
Bio-Techne Corporation has multiple valuation anchors: DCF Intrinsic Value: $29.07 | Peer Relative Fair Value: $68.09 | Wall Street Analyst Target: $59.17 (implying +2.1% upside). A convergence of these signals offers higher conviction.
Bio-Techne Corporation displays good financial health with a composite quality score of 65/100, supported by a Altman Z-Score of 9.7 (safe zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 3.4%.
Bio-Techne Corporation pays a 0.5% dividend yield, covered by a 69% payout ratio with 0 years of growth, supplemented by a 3.0% buyback yield.
Bio-Techne Corporation's current growth trajectory is Stable. The company achieved +5.2% 1Y revenue growth and -56.2% 1Y EPS growth, compared to its 3Y revenue CAGR of +3.3%.
Wall Street consensus is Buy based on 25 analysts, beating EPS expectations in 50% of recent quarters with a -1-quarter streak. The consensus price target represents a +2.1% change from current levels.
Investment risks for Bio-Techne Corporation include: -39.3% 1-year max drawdown. Volatility risk is characterized by a beta of 1.05x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.